These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34590038)

  • 1. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
    Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
    JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Patients with
    Sanchis-Borja M; Guisier F; Swalduz A; Curcio H; Basse V; Maritaz C; Chouaid C; Auliac JB
    Onco Targets Ther; 2024; 17():439-448. PubMed ID: 38836187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSCLC patients with rare
    Wang H; Yu Q; Shi L; Hou Q; Dan L; Liang C; Hong X; Zhao Y; Ning R
    Front Oncol; 2022; 12():1054593. PubMed ID: 36505860
    [No Abstract]   [Full Text] [Related]  

  • 5. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
    He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
    World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.
    Yu N; Xu Y; Wang X; Sun C; Qiu S; Guo Y; Bai M; Huang Y; Ma K
    Oncologist; 2021 Nov; 26(11):e1903-e1908. PubMed ID: 34396638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
    J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon
    Yang JC; Schuler M; Popat S; Miura S; Park K; Passaro A; De Marinis F; Solca F; Märten A; Kim ES
    Front Oncol; 2022; 12():834704. PubMed ID: 35574304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
    Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report.
    Zhao Y; Chen Y; Huang H; Li X; Shao L; Ding H
    Onco Targets Ther; 2021; 14():3063-3067. PubMed ID: 33994798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
    Zhang Y; He B; Zhou D; Li M; Hu C
    Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report.
    Han J; Wang Y; Zhong L; Zhou H; Yu M; Li Y; Lu Y; Wang Y; Zhu J
    Precis Clin Med; 2018 Dec; 1(3):129-133. PubMed ID: 35692703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
    Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.